Stockscreener 앱 받기
1.48
10.84%
-0.18
시장 영업 전:
1.55
0.07
+4.73%
전일 마감가:
$1.66
열려 있는:
$1.67
하루 거래량:
493.02K
Relative Volume:
2.41
시가총액:
$64.28M
수익:
$106.79M
순이익/손실:
$-8.73M
주가수익비율:
-7.40
EPS:
-0.2
순현금흐름:
$10.81M
1주 성능:
-16.38%
1개월 성능:
-32.42%
6개월 성능:
-49.14%
1년 성능:
-68.38%
1일 변동 폭
$1.46
$1.6719
1주일 범위
$1.46
$1.80
52주 변동 폭
$1.46
$4.93
Harvard Bioscience Inc Stock (HBIO) Company Profile
명칭
Harvard Bioscience Inc
전화
(508) 893-8999
주소
84 OCTOBER HILL RD, HOLLISTON, MA
HBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HBIO
Harvard Bioscience Inc
|
1.48 | 64.28M | 106.79M | -8.73M | 10.81M | -0.20 |
|
ISRG
Intuitive Surgical Inc
|
588.50 | 209.89B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
227.21 | 68.23B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
91.65 | 45.33B | 9.76B | 1.16B | 665.00M | 2.34 |
|
RMD
Resmed Inc
|
237.18 | 34.84B | 4.93B | 1.25B | 1.38B | 8.47 |
|
WST
West Pharmaceutical Services Inc
|
330.47 | 23.97B | 2.88B | 499.60M | 321.60M | 6.74 |
Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-03-10 | 업그레이드 | The Benchmark Company | Speculative Buy → Buy |
| 2021-01-07 | 업그레이드 | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-09 | 개시 | Northland Capital | Outperform |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2019-07-08 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-01-24 | 재확인 | Janney | Buy |
| 2018-01-23 | 재확인 | The Benchmark Company | Buy |
| 2016-11-17 | 개시 | Singular Research | Buy |
| 2015-07-28 | 개시 | The Benchmark Company | Buy |
모두보기
Harvard Bioscience Inc 주식(HBIO)의 최신 뉴스
JPMorgan Chase & Co. Boosts Stock Holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO) - Defense World
HBIO stock touches 52-week low at $1.7 amid market challenges - Investing.com India
Pre-market Movers: SLGL, VIRX, ANVS, CUTR... - RTTNews
Harvard Bioscience, Inc. (NASDAQ:HBIO) Short Interest Up 22.8% in January - MarketBeat
Assenagon Asset Management S.A. Sells 132,516 Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) - Defense World
HBIO Stock Touches 52-Week Low at $1.79 Amid Market Challenges - Investing.com Canada
HBIO Stock Touches 52-Week Low at $1.79 Amid Market Challenges By Investing.com - Investing.com South Africa
Microelectrode Array In Vitro Market to Reach US$ 25.67 Million by 2031, Driven by Neuroscience and Animal Testing Alternatives - GlobeNewswire Inc.
Barclays PLC Has $157,000 Position in Harvard Bioscience, Inc. (NASDAQ:HBIO) - Defense World
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Acquired by Barclays PLC - Defense World
bioMérieux Gains FDA Clearance for Tropical Fever Test - MSN
One Harvard Bioscience Insider Raised Their Stake In The Previous Year - Yahoo Finance
Harvard Bioscience (NASDAQ:HBIO) Stock Price Passes Below 200-Day Moving AverageTime to Sell? - MarketBeat
Jane Street Group LLC Sells 37,349 Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) - Defense World
Dallas' Colossal Biosciences Becomes Texas' First Decacorn, Securing $10.2B Valuation With Series C Funding - dallasinnovates.com
LeddarTech Reports on Participation in CES 2025 - The Manila Times
Harvard Bioscience, Inc. to Participate in the Sidoti Micro Cap Conference - The Manila Times
Harvard Bioscience CEO to Present at Sidoti Micro Cap Conference on January 22 - StockTitan
Further weakness as Harvard Bioscience (NASDAQ:HBIO) drops 11% this week, taking three-year losses to 69% - Simply Wall St
HBIO stock touches 52-week low at $1.95 amid market challenges By Investing.com - Investing.com South Africa
HBIO stock touches 52-week low at $1.95 amid market challenges - Investing.com Australia
Harvard Bioscience, Inc. (NASDAQ:HBIO) Position Boosted by Barclays PLC - Defense World
Geode Capital Management LLC Boosts Stock Holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO) - Defense World
State Street Corp Acquires 7,763 Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) - Defense World
HBIO stock touches 52-week low at $1.99 amid market challenges - Investing.com Nigeria
HBIO stock touches 52-week low at $1.99 amid market challenges By Investing.com - Investing.com South Africa
Lexaria Bioscience Forms Elite Scientific Advisory Board with Harvard Medical School Expert - StockTitan
Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience - Yahoo Finance
BNP Paribas Financial Markets Has $201,000 Stock Holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO) - Defense World
BNP Paribas Financial Markets Boosts Stock Position in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Lexaria Bioscience Taps Harvard Medical Expert to Accelerate GLP-1 & Hypertension Drug Development - StockTitan
Harvard Bioscience, Inc. (NASDAQ:HBIO) Short Interest Update - Defense World
Harvard Bioscience (HBIO) Stock Dips Amid Industry Movements - GuruFocus.com
Harvard Bioscience (NASDAQ:HBIO) Stock Passes Below 200-Day Moving AverageTime to Sell? - MarketBeat
Harvard Bioscience (HBIO) Stock Drops Amid Market Volatility - GuruFocus.com
3 US Penny Stocks With Market Caps Under $100M - Simply Wall St
Harvard Bioscience files $100M mixed securities shelf - MSN
In-Vitro and In-Vivo Micro Electrode Array Market to Grow by USD 7 Million (2024-2028), Driven by MEA Applications in Neuroscience Research, with AI Driving Market TransformationTechnavio - The Malaysian Reserve
Prepacked Chromatography Columns Market Size Is Expected To - GlobeNewswire
272 Capital LP Has $1.54 Million Position in Harvard Bioscience, Inc. (NASDAQ:HBIO) - MarketBeat
Harvard Bioscience (HBIO) Stock Surges Amid Positive Analyst Rat - GuruFocus.com
Harvard Bioscience, Inc. (NASDAQ:HBIO) Short Interest Up 13.8% in October - MarketBeat
Ayla Majid becomes first South Asian ACCA president - The Accountant Online
Harvard Bioscience Inc (HBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
10.10%
0.93%
자본화:
|
볼륨(24시간):